1. Signaling Pathways
  2. Immunology/Inflammation
  3. CTLA-4
  4. CTLA-4 Inhibitor

CTLA-4 Inhibitor

CTLA-4 Inhibitors (21):

Cat. No. Product Name Effect Purity
  • HY-P9901
    Ipilimumab
    Inhibitor 99.88%
    Ipilimumab is a fully human monoclonal antibody IgG1κ that blocks the inhibitory receptor cytotoxic T lymphocyte antigen 4 (CTLA-4) on T cells. Ipilimumab can be used in unresectable or metastatic melanoma (MM) studies.
  • HY-P99132
    Anti-Mouse CTLA-4 Antibody (9D9)
    Inhibitor ≥98.0%
    Anti-Mouse CTLA-4 Antibody (9D9) is an anti-mouse CTLA-4 IgG2b monoclonal antibody. Anti-Mouse CTLA-4 Antibody (9D9) can bind to CTLA-4 and block its binding to B7. Anti-Mouse CTLA-4 Antibody (9D9) enhances T cell function by increasing the ratio of CD8+ T cells to regulatory T cells (Tregs). Anti-Mouse CTLA-4 Antibody (9D9) can be used for research on cancer such as colon cancer and melanoma.
  • HY-P99117
    Cadonilimab
    Inhibitor 99.29%
    Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody targeting PD1/CTLA4. Cadonilimab blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC). Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC).
  • HY-P991139
    Futermestotug
    Inhibitor
    Futermestotug is a humanized immunoglobulin G1-κ monoclonal antibody targeting human cytotoxic T-lymphocyte associated protein 4 (CTLA4). Futermestotug is promising for research of various malignant tumors.
  • HY-P991566
    KD6001
    Inhibitor
    KD6001 is a humanized IgG1κ monoclonal antibody, targeting CTLA4. KD6001 significantly disrupts CTLA-4 interactions with CD80 (IC50: 16 ng/mL) and CD86. KD6001 enhances IL-2 and IFNγ expression in PHA-activated human lymphocytes and exhibits potent antitumor effects. KD6001 effectively inhibits tumor growth in MC38, B16, and Hepa1-6 tumor mice model. KD6001 can be used for cancers research, such as advanced melanoma, hepatocellular carcinoma and liver cancer.
  • HY-108829A
    Abatacept (powder)
    Inhibitor
    Abatacept (CTLA4lg; BMS-188667) powder is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains). Abatacept powder is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases.
  • HY-P99166
    Vudalimab
    Inhibitor ≥99.0%
    Vudalimab is a potent dual PD-1 and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation.
  • HY-P99484
    Botensilimab
    Inhibitor 99.00%
    Botensilimab (AGEN 1181), a human anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody, is an innate and adaptive immune activator. Botensilimab can be used for the research of cancer.
  • HY-P990042
    Gotistobart
    Inhibitor ≥99.0%
    Gotistobart (ONC-392) is a humanized anti-CTLA-4 antibody that confers immunotherapeutic effect by selective depletion of regulatory T cells (Treg) in the tumor microenvironment.
  • HY-19916A
    Lisavanbulin dihydrochloride
    Inhibitor 99.74%
    Lisavanbulin (BAL-101553) dihydrochloride is the prodrug of the microtubule targeting agent Avanbulin (BAL 27862) (HY-106008). Lisavanbulin dihydrochloride exhibits antitumor activity, especially in tumors that express high levels of end-binding protein 1. Lisavanbulin dihydrochloride has ability to target tumor cell proliferation and affects the tumor microenvironment by reducing tumor microvasculature. Lisavanbulin dihydrochloride is also a spindle assembly checkpoint activator, agonistic anti-CD40 antibody, and double immune checkpoint blockade (anti-PD-1 and anti-CTLA-4). Lisavanbulin dihydrochloride induces cell cycle arrest and subsequent death or aberrant chromosome segregation. Lisavanbulin dihydrochloride can be studied in research for diffuse large B cell lymphoma (DLBCL) and glioblastoma.
  • HY-P99514
    Zalifrelimab
    Inhibitor 98.28%
    Zalifrelimab (AGEN1884) is a fully human IgG1 monoclonal antibody targeting CTLA-4 (CTLA-4). Zalifrelimab antagonizes the inhibitory checkpoints of immune cell activation regulated by CTLA-4 signaling.
  • HY-19916
    Lisavanbulin
    Inhibitor 99.24%
    Lisavanbulin (BAL-101553) is the prodrug of the microtubule targeting agent Avanbulin (BAL 27862) (HY-106008). Lisavanbulin is a BBB-penetrant and orally active antitumor agent, especially in tumors that express high levels of end-binding protein 1. Lisavanbulin has ability to target tumor cell proliferation and affects the tumor microenvironment by reducing tumor microvasculature. Lisavanbulin is also a spindle assembly checkpoint activator, agonistic anti-CD40 antibody, and double immune checkpoint blockade (anti-PD-1 and anti-CTLA-4). Lisavanbulin induces cell cycle arrest and subsequent death or aberrant chromosome segregation. Lisavanbulin can be studied in research for diffuse large B cell lymphoma (DLBCL) and glioblastoma.
  • HY-P99809
    Quavonlimab
    Inhibitor ≥99.0%
    Quavonlimab (MK-1308) is a novel anti-CTLA-4 antibody.
  • HY-P990256
    Anti-Mouse CTLA-4/CD152 (LALA-PG) Antibody (9D9)
    Inhibitor
    Anti-Mouse CTLA-4/CD152 (LALA-PG) Antibody (9D9) is a mouse-derived IgG2a κ type antibody inhibitor targeting to mouse CTLA-4/CD152. Anti-Mouse CTLA-4/CD152 (LALA-PG) Antibody (9D9) contains a LALA-PG mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse CTLA-4/CD152 (LALA-PG) Antibody (9D9) can be used for the researches of cancer and immunology, such as colon.
  • HY-P99540
    Tuvonralimab
    Inhibitor 99.14%
    Tuvonralimab (PSB-205) is a humanized IgG1 monoclonal antibody against CTLA-4. Tuvonralimab can be used in the research of tumors. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
  • HY-P990789
    Anti-Mouse CTLA-4 Antibody (9H10)
    Inhibitor
    Anti-Mouse CTLA-4 Antibody (9H10) is a kind of syrian hamster IgG antibody inhibitor, targeting to CTLA-4. Anti-Mouse CTLA-4 Antibody (9H10) binds mouse CTLA-4 and blocks the interaction between CTLA-4 and its ligand. Anti-Mouse CTLA-4 Antibody (9H10) shows potent anti-tumor effect in various tumor models, such as breast and colon cancer.
  • HY-P99760
    Nurulimab
    Inhibitor
    Nurulimab (BCD-145) is an anti-cytotoxic T lymphocyte antigen-4 (anti-CTLA-4) human monoclonal antibody. Nurulimab can be can be used in research of melanoma.
  • HY-P99714
    Lorigerlimab
    Inhibitor
    Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting antibody (DART). Lorigerlimab can block PD-1 and CTLA-4, and improves T-cell responses. Lorigerlimab can be used for research of metastatic castration-resistant prostate cancer (mCRPC).
  • HY-P990041
    Firastotug
    Inhibitor
    Firastotug is an IgG1κ antibody targeting CTLA4. CTLA4 is a cytotoxic T lymphocyte-associated protein and a key immune checkpoint in the fields of autoimmunity and cancer.
  • HY-P990048
    Muzastotug
    Inhibitor 99.48%
    Muzastotug is a humanized immunoglobulin G1-kappa, anti-CTLA4 monoclonal antibody. Muzastotug is an immunostimulant and antineoplastic.